div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails2jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=3Page 3button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=3 data-page=3 class=ts-thumb lazyload alt=Page 3: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails3jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=4Page 4button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=4 data-page=4 class=ts-thumb lazyload alt=Page 4: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails4jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=5Page 5button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=5 data-page=5 class=ts-thumb lazyload alt=Page 5: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails5jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=6Page 6button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=6 data-page=6 class=ts-thumb lazyload alt=Page 6: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails6jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=7Page 7button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=7 data-page=7 class=ts-thumb lazyload alt=Page 7: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails7jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=8Page 8button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=8 data-page=8 class=ts-thumb lazyload alt=Page 8: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails8jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=9Page 9button div class=ts-imageimg data-url=neuroendocrine-tumors-2017-1-25-trial-inc-18424-268a-a-randomizedhtmlpage=9 data-page=9 class=ts-thumb lazyload alt=Page 9: Neuroendocrine Tumors Napoli · 2017 1 25 · Trial INC 18424-268— A randomized double-blind—phase 2 study of ruxolitinib or placebo in combination with capecitabine in subjects loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader035vdocumentsusreader035viewer20220714106104c7b3c4f42e5c450107b5html5thumbnails9jpg width=140 height=200 divdiv
